Truist Cuts Exponent Price Target to $90 While Reaffirming Buy Rating

Truist Securities on 2 November lowered its 12-month price objective for engineering and scientific consulting firm Exponent, Inc. (NASDAQ: EXPO) to $90 from $100 but reiterated a Buy recommendation, according to market updates circulated to clients. The brokerage said the company’s specialized work in failure analysis could see stronger demand as artificial-intelligence applications proliferate, yet it also cautioned that greater automation might compress billable hours for consultants across the industry.

The revised target follows the release of Exponent’s third-quarter results, which pointed to continued top-line expansion driven by a diverse project mix. For the quarter ended 27 September 2025, total revenue grew 8 percent year over year to $147.1 million. Revenue before reimbursements—a metric the company uses to reflect core consulting activity—rose 10 percent to $137.1 million, compared with $125.1 million in the same period of 2024.

Management attributed the performance to broad-based growth, with particularly strong contributions from dispute-related assignments in the energy, transportation, life-sciences and construction markets. The firm noted that clients involved in litigation or arbitration increasingly require multidisciplinary expertise to quantify damages and assess technical evidence, areas where Exponent maintains longstanding capabilities.

Truist’s analysts highlighted the dual impact of artificial intelligence on the consulting sector. On one hand, organizations integrating AI into safety-critical systems are turning to external specialists to validate algorithms, test robustness and establish compliance frameworks. Exponent’s experience in root-cause investigations, materials science and human-factors engineering positions it to capture that business, the note said. On the other hand, efficiencies gained from machine-learning tools could shorten project timelines, potentially curbing revenue that is often billed on an hourly basis.

Despite those uncertainties, Truist kept its Buy rating, citing the company’s consistent record of expanding into emerging technical niches and its balance-sheet flexibility. As of the end of the third quarter, Exponent carried no long-term debt and reported cash and short-term investments of $285.5 million. The analyst team added that the firm’s exposure to multiple industries reduces dependency on any single end market, an attribute viewed as advantageous during periods of economic fluctuation.

Inside the quarterly report, Exponent emphasized rising demand for assistance with responsible innovation. Clients deploying AI-enabled products and infrastructure are seeking guidance on risk mitigation, regulatory requirements and post-deployment monitoring. The company’s engineers and scientists have been engaged to evaluate autonomous vehicle systems, medical devices using predictive algorithms and energy installations relying on advanced control software.

Imagem: imagem internet 41

Truist’s lowered price target reflects a valuation framework that balances anticipated revenue growth against potential margin pressure from automation and macroeconomic headwinds affecting professional-services spending. The new $90 objective implies roughly 22 times the firm’s projected 2026 earnings, a level the brokerage considers appropriate given Exponent’s historical trading range and dividend profile.

Headquartered in Menlo Park, California, Exponent provides consulting and laboratory services aimed at solving complex technical problems. The company employs more than 1,000 engineers, scientists, physicians and regulatory specialists who work out of offices in the United States, Europe and Asia. Public filings with the U.S. Securities and Exchange Commission list its business segments as engineering and other scientific, with engagements spanning product development, failure investigation, environmental impact and health-hazard assessment.

While Truist continues to favor the stock, it acknowledged that broader adoption of generative AI across the consulting landscape could reshape pricing models and staffing needs over the medium term. For now, the brokerage expects Exponent’s diversified portfolio and expertise in highly regulated domains to underpin steady earnings growth.

Crédito da imagem: Exponent, Inc.